Rick Wise

what you're charging Vitor with, what you're tasking Vitor with as he steps into the role

if there would be some upside to this thoughtfully prudent guidance, in the next two, four, six quarters

You're not that far away. You said, "I think there's more room ahead" just maybe expand on your thinking there

I'm more fascinated and hoping to dig in further on the 3 major initiatives, operating model change and the commercial team alignment

my initial back of the envelope calculation suggests that just as I do the math, that implies sort of a step down in operating margins relative -- flat or down

Your $1 billion share repurchase announcement over the next 12 to 18 months certainly seems like a positive to me

how specifically are you going to tackle the growth rate factors that impacted this quarter?

talk us through your expectations for how the '25-year is going to unfold. I mean maybe the cadence of the year

where do we go from here on the margin front? How big a driver of your operating margin goals is gross margin?

is this still the ASC a net positive given maybe potentially lower WATCHMAN implants

How do we think about this, is renal innovation here now, given the recent approvals?

maybe talk if you would about not tariffs specifically, but sort of other aspects of the trade wars

Maybe you can help us better understand where the upside and where the risks are

are you seeing -- are you hearing the same thing that I heard? I mean, obviously, as the year unfolds and as you -- as education expands

have you shaded your TAVR expectations in some way with your comments and guided in the first quarter, is it any different

What gets the revenues growing again? What gets the margin story stabilized

you expected, if I recall correctly, second half '25 filing. Is that on track

what dynamics internationally drove I&A at double the rate of procedure growth

talk about a couple of initiatives that others are focused on. And to what degree is this important to Intuitive Surgical

you also highlighted digital subscription. And I'm just not sure if I've personally, maybe I've missed it, heard that language

About 9 million procedures in direct line of sight. I went back and looked at '24 and you all said 7 million at the time

how much do you think the original capital cost is versus Medicare coverage and commercial rates?

when do we get past the when is bariatrics less of a drag? Seems like it's been going on for a while

there would be additional features, additional software different additional capabilities. And I was hoping you could expand on that

as things evolve and as dV5 rolls out, it's early to say what's next. But how are you thinking about what's next broadly

OUS growth was particularly robust at 24%. Maybe you can talk about the drivers there, the sustainability of the drivers

I missed what you said about after hours surgery growth. I just didn't get the number. But after hours surgery and you recently hired a new leader

What accelerates -- what drives the next phase of growth there? And specifically, when is -- what level of sales or what has to happen?

maybe help us understand what areas this -- in what way this might enhance da Vinci 5? Will it open up new procedures? Will it be about productivity?

can you approximate your current mix of full AI autonomous coding versus primarily traditional computer-assisted coding

Consensus is a shade over $2 billion for Q2 coming into the call. Do you feel like that adequately reflects a reasonable midpoint

Is it more likely we're going to see additional tuck-in growth-enhancing, margin-enhancing deals sooner rather than later

what's the relative importance over the next 12 months in terms of observing that progress

Maybe talk us through the next big milestone there, time lines there. And just maybe remind us, if you would, the impact of this process going on

the drinking water business, you've kept it for all the reasons you said. And I think Bryan's words were the potential to unlock additional value here

tariffs are a bigger headwind, you were very clear. But offsetting that is the business momentum is the lower -- is the lower FX

Just where are we, and where are you in realizing this opportunity? What are you expecting?

help us understand that upper end of the guidance range and the things that you're counting on to go right

you didn't raise by overall by the beat, you left sales unchanged EPS less than the EPS beat

Help us better understand what's embedded at a high level in that thinking

where are we in that Wave 1 rollout process and impact?

You've trained several hundred customers. My impression, if I remember correctly from AUS that you hope to train maybe 1,000 by year end

which of the products in the second half are going to be most impactful